|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.95 USD | +9.12% |
|
+11.58% | -14.13% |
| 05-14 | Transcript : NRx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
| 05-06 | NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data | DJ |
On February 16, 2023, Mr. Robert Besthof, NRx Pharmaceuticals, Inc.'s Head of Operations and Chief Commercial Officer, notified the Company of his resignation. Mr. Besthof will continue to work at the company in order to effect an orderly transition of his responsibilities. Mr. Besthof's last day with the company has yet to be agreed.
The company is currently in discussions with Mr. Besthof regarding a continuing role as a part-time advisor to the company.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.13% | 41.52M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
NRX PHARMACEUTICALS, INC. 
